Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. Among authors: ozaka m. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis.
Nakayama I, Chin K, Matsushima T, Takahari D, Ogura M, Shinozaki E, Suenaga M, Ozaka M, Wakatsuki T, Ichimura T, Hiroki O, Yamaguchi K. Nakayama I, et al. Among authors: ozaka m. Int J Clin Oncol. 2017 Dec;22(6):1060-1068. doi: 10.1007/s10147-017-1164-4. Epub 2017 Jul 26. Int J Clin Oncol. 2017. PMID: 28748355 Clinical Trial.
A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma.
Murahashi S, Takahari D, Wakatsuki T, Fukuda N, Ichimura T, Ogura M, Ozaka M, Shinozaki E, Nakayama I, Matsushima T, Osumi H, Chin K, Yamaguchi K. Murahashi S, et al. Among authors: ozaka m. Int J Clin Oncol. 2018 Feb;23(1):92-97. doi: 10.1007/s10147-017-1192-0. Epub 2017 Sep 14. Int J Clin Oncol. 2018. PMID: 28913565 Clinical Trial.
Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Mizusawa J, Fukutomi A, Katayama H, Ishii H, Ioka T, Okusaka T, Ueno H, Ueno M, Ikeda M, Mizuno N, Ozaka M, Fukuda H, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. Mizusawa J, et al. Among authors: ozaka m. Pancreatology. 2018 Oct;18(7):841-845. doi: 10.1016/j.pan.2018.07.007. Epub 2018 Jul 27. Pancreatology. 2018. PMID: 30075908 Clinical Trial.
Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Shirasu H, Todaka A, Omae K, Fujii H, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Kobayashi M, Fukutomi A. Shirasu H, et al. Among authors: ozaka m. Cancer Sci. 2019 Feb;110(2):707-716. doi: 10.1111/cas.13883. Epub 2018 Dec 12. Cancer Sci. 2019. PMID: 30447099 Free PMC article.
FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I, Kamei K, Omae K, Suzuki S, Matsuoka H, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi M, Todaka A, Fukutomi A. Matsumoto I, et al. Among authors: ozaka m. Pancreatology. 2019 Mar;19(2):296-301. doi: 10.1016/j.pan.2019.01.001. Epub 2019 Jan 4. Pancreatology. 2019. PMID: 30638853 Clinical Trial.
151 results